SightfileU.S. market data from official filings

CARIS LIFE SCIENCES INC (CAI)

Name: CARIS LIFE SCIENCES INC (CAI) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0002019410 · EDGAR filings · Updated 2026-07-13

CARIS LIFE SCIENCES INC (CAI) has reported institutional ownership of 55.5%, with 201 institutional managers holding positions valued at $2.80B per the latest 13F reporting period.

Institutional ownership

55.5%

Institutional managers

201

Reported 13F value

$2.80B

Insider activity

55 trans.

−$756.4K net selling

Latest updates

2026-07-13 — Insider transaction reported (Form 4)
2026-06-16 — CERT filed
2026-06-16 — 8-A12B filed
2026-06-05 — Current report (8-K) filed
2026-06-02 — Insider transaction reported (Form 4)
2026-06-02 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, CARIS LIFE SCIENCES INC has 201 institutional holders and institutional ownership of 55.5%.

Insider activity

Insiders reported 55 transactions (4 buys, 2 sells) across 20 reporting insiders, with a net reported value of −$756.4K.

Related companies

SUPERNUS PHARMACEUTICALS (SUPN) · VERACYTE INC (VCYT) · DENALI THERAPEUTICS INC (DNLI) · IMMUNOVANT INC (IMVT) · DISC MEDICINE INC (IRON) · HAEMONETICS CORP MASS (HAE)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-13.